eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | diffuse large b-cell lymphoma |
| Comorbidity | C0023434|chronic lymphocytic leukemia |
| Sentences | 4 |
| PubMedID- 24135829 | Ercc5 expression was significantly higher in dlbcl when compared with that in chronic lymphocytic leukemia (figure 6a(i)). |
| PubMedID- 22684281 | The first anticancer mab registered was rituximab (rituxan®), a chimeric anti-cd20 antibody, that demonstrated activity in relapsing follicular lymphoma in a phase 1 study.1 rituximab was registered for the treatment of follicular lymphoma, then diffuse large b cell lymphoma in combination with chemotherapy, and chronic lymphocytic leukemia (cll).2-4 rituximab has secondarily demonstrated efficacy in other b cell lymphomas, as well as in autoimmune cytopenias, and b cell-driven diseases like rheumatoid arthritis.5-7 because of this efficacy, other mabs targeting the cd20 antigen or other lymphoid antigens were developed for the treatment of lymphomas. |
| PubMedID- 24963449 | Richter's transformation (rt) represents the development of high grade lymphoma, most commonly diffuse large b-cell lymphoma, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll). |
| PubMedID- 25136531 | diffuse large b-cell lymphoma in patients with chronic lymphocytic leukemia: a single center experience. |
Page: 1